Neurogranin

Neurogranin Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
NEN-H5144
Human
E. coli
Human Neurogranin Protein, His Tag
Total: 1
  • 1

Neurogranin Background

Neurogranin is as a small protein encoded by the NRGN gene. it is a calmodulin-binding protein expressed primarily in the brain, particularly in dendritic spines, and participating in the protein kinase C signaling pathway. Neurogranin is the main postsynaptic protein regulating the availability of calmodulin, binding to it in the absence of calcium. Phosphorylation by protein kinase C lowers its binding ability. It is a potential biomarker of neurological and mental diseases.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SemzuvolimabdB4; UB-421; mAb-B4Phase 3 ClinicalUnited Biomedical IncHIV Infections
Details
ITV 1(Nonindustrial source)ITV-1Phase 3 ClinicalSynexa Life Sciences, Immunotech LaboratoriesHIV Infections
Details
RB-0003RB-0003; BNT-111Phase 2 ClinicalBiontech Se, TronMelanoma
Details
VRC-01-LSVRC-HIVMAB-080-00-AB; VRC-01-LSPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
VRC-07-523VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380Phase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics IncAcquired Immunodeficiency Syndrome; HIV Infections; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity
Details
GEN-009GEN-009Phase 2 ClinicalGenocea Biosciences IncSkin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung
Details
TregalizumabhB-F5; BT-061Phase 2 ClinicalBiotest Pharma GmbhDrug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma
Details
MVA-ELMVA-EBNA1/LMP2Phase 2 ClinicalChinese University Of Hong Kong (Cuhk), Cancer Research UKHead and Neck Neoplasms; Stomach Neoplasms; Nasopharyngeal Neoplasms; Lymphoproliferative Disorders; Epstein-Barr Virus Infections; Lymphoma
Details
VRC-HIVMAB091-00-ABN6LS; Z258‐N6LS; VRC-HIVMAB091-00-ABPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
IMCY-0141IMCY-0141Phase 2 ClinicalImcyse SaMultiple Sclerosis, Relapsing-Remitting
Details
Autologous Regulatory Т-cell TherapyPhase 2 ClinicalInstitute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of BelarusScleroderma, Systemic
Details
CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene)CD4CAR (Icell Gene)Phase 1 ClinicalStony Brook University School Of Medicine, Icell Gene Therapeutics (Int'L) Ltd, University Of LouisvilleLeukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell; Leukemia, T-Cell
Details
T-allo-10T-allo-10Phase 1 ClinicalStanford UniversityHematologic Diseases; Leukemia; Graft vs Host Disease; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin
Details
Anti-CD4 CAR T-cell therapy (University of Pennsylvania)CAR-C34ZFNPhase 1 ClinicalUniversity Of PennsylvaniaHIV Infections; HIV Seropositivity
Details
10E8.4/iMab (Aaron Diamond AIDS Research Center)TMB-370Phase 1 ClinicalAaron Diamond Aids Research Center For The City Of New York, IncHIV Infections
Details
CALRLong36 peptide (Herlev Hospital)Phase 1 ClinicalHerlev HospitalMyeloproliferative Disorders
Details
VRC-HIVMAB060-00-ABVRC-HIVMAB060-00-AB; VRC01Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
VRC-HIVMAB0115-00-ABPhase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections; HIV Seropositivity
Details
SCRI-E2CAR_EGFRtv1SCRI-E2CAR_EGFRtv1Phase 1 ClinicalUmoja BioPharma IncOsteosarcoma
Details
CD4^LVFOXP3 Treg-like cell therapyCD4^LVFOXP3Phase 1 ClinicalStanford UniversityPolyendocrinopathies, Autoimmune
Details
TMB-365TMB-365Phase 1 ClinicalTaimed Biologics IncHIV Infections
Details
LB-1901LB1901; LB-1901Phase 1 ClinicalLymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous
Details
IT-1208 (Kyowa Hakko Kirin)IT-1208Phase 1 ClinicalKyowa Hakko Kirin Co LtdNeoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
IbalizumabHu5A8; TMB-355; TNX-355; 5ABApprovedBiogen Inc特罗格佐, TrogarzoUnited StatesHIV InfectionsTheratechnologies Inc2018-03-06HIV Infections
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland